Portable, Point-of-Care Solution
By leveraging the principles of Raman Spectroscopy, Seraspec® represents a paradigm shift away from current methods for screening and identification of dangerous bacterial, viral and fungal pathogens. Our patent pending technology and method of detection* effectively eliminates the need for time-consuming and costly laboratory-based methods of specimen collection, processing and pathogen identification. Safety, efficiency, accuracy and profitability are simultaneously enhanced through a portable, point-of-care technology for real-time pathogen detection and identification. A higher power just got involved in the fight against infection.
A Molecular Fingerprint
Reagentless, Fully-Automated Detection
The Seraspec® employs an enclosed assembly of optical components allowing for real-time Raman spectral measurements that generate a unique molecular fingerprint for pathogen identification. The system also incorporates proprietary signal processing and identification algorithms to distinguish targeted pathogens from confounding background interference facilitating real-time identification at the point-of-care. This disruptive technology will enable health care providers to render more efficient healthcare decisions and optimize clinical outcomes.
Healthcare faces a daunting global crisis resulting from the convergence of accelerating antimicrobial resistance and novel pandemic viruses. Acting swiftly to treat infections with broad-based antibiotics appears prudent when the alternative is laboratory-based verification spanning several days. This “shotgun” approach essentially guarantees that the antimicrobial resistance crisis will continue to escalate.
Our mission as a company is to produce quality, cost-effective technologies for health care providers to optimize clinical decision making in our globally integrated society. With the right tools and partners, we hope and believe that this crisis will be averted.
Chief Executive Officer
Jim serves as Chief Executive Officer of Seraph Biosciences bringing over 20 years of executive management, sales, and marketing experience. Jim began his career as President & Chief Operating officer of Rootlevel, Inc. where he established the company as one of the Midwest’s leading web application firms. Jim also served as Executive Vice President & Managing Director of Picnic New Media for Ringside Creative and Cutters Studios where he lead the interactive and mobile development efforts. Prior to joining Seraph Biosciences, served as Chief Marketing Officer of Medical Engineering Partners, LLC.
Chief Operations Officer
Braden serves as Chief Operations Officer of Seraph Biosciences bringing over 19 years of experience in medical devices. He has launched more than one hundred products through the FDA regulated process. As Senior Director of Business Development and Strategy for Stryker Corp., he successfully led $235M worth of transactions and started 2 different divisions for the company. Prior to joining Seraph Biosciences, Braden served as a Mentor-in-Residence at the University of Michigan’s Tech Transfer program and principal of 1021 Partners aimed at helping early stage companies build and grow their businesses.
Gregory W. Auner, PhD
Founder & Chief Science & Innovation Officer
Dr. Auner is a co-founder and Chief Science Officer of Seraph Biosciences. He holds the Strauss TEAMS Endowed Chair and is a Professor of Electrical and Computer Engineering, Biomedical Engineering, and Material Science at Wayne State University. He is also the founder and Director of the Smart Sensors and Integrated Microsystems Program. Dr. Auner has over 30 patents (issued and pending) in the last few years for chemical, biomedical, and environmental sensors and microsystems and has been granted more than $35 million in research grants and contracts as principle investigator. Along with co-founding Seraph Biosciences, he is the Chief Technology Officer and Co-Founder of Visca, LLC, and Medical Engineering Partners, LLC
Hür Köser, PhD
Chief Product & Technology Officer
Dr. Hür Köser serves as Chief Product and Technology Officer of Seraph Biosciences, Inc. He brings over 17 years of experience as an accomplished academic researcher and technical entrepreneur. As an electrical engineering professor at Yale University, Dr. Köser conducted internationally recognized research in Nano-biotechnology, microsystems, bio-sensors, and microfluidics. He has also served as a Chief Technology Officer and advisor to several diagnostic companies with commercial applications ranging from neurodegenerative disease biomarkers to liquid biopsy analysis. He holds a B.S., M.S., and Ph.D in Electrical Engineering from the Massachusetts Institute of Technology.
Vice President - Engineering
Shane Trexler serves as Vice President of Engineering for Seraph Biosciences, Inc. drawing upon 10 plus years of laboratory research, engineering design, and business management. As the founder and president of the Sustainable Consulting Group, Shane successfully managed engineering design efforts for both startup companies and established medical device and engineering clients throughout the United States as well as Eastern Africa. He has consulted in the design, development, and prototypes of components and systems for various medical device companies.
Director - Software Development
Naga Puttagunta serves as Director of Software Development for Seraph Biosciences, Inc. with over 20 years of experience in commercial software development, cloud architecture, and data security systems. Most recently, Naga served as Vice President of Software Engineering for Aptiv, a publicly traded automotive parts company specializing in systems development for signal and power solutions as well as advanced safety and user experience in mobility. In addition to his technical expertise, Naga has a proven track record of establishing, growing, and leading large software teams.
Ehsan Majidi, PhD
Lead A.I. Scientist
Dr. Majidi serves as the Lead Artificial Intelligence Scientist for Seraph Biosciences, Inc. He is charged with writing and implementing Seraph’s proprietary algorithms, which are foundational to Seraspec’s automated diagnostic software. Prior to joining Seraph Biosciences, Dr. Majidi was a Senior Software Engineer for Delphi Automotive and Senior Software Engineer and researcher in autonomous vehicles for General Motors. He earned his doctorate from Wayne State University’s College of Engineering specializing in software development, deep learning, and neural networks.
Advanced Quality Engineer
Lamees Almawri serves as an Advanced Quality Engineer for Seraph Biosciences, Inc. She is responsible for executing Seraspec’s Quality System with the management team as well as the company’s external suppliers. Lamees holds a BS in Biological Sciences from the University of Michigan-Dearborn and an MS in Biomedical Engineering from Wayne State University. She has a combined 4 years of research experience at Beaumont Health and Henry Ford Health System and 3 years of quality and testing experience in the medical device industry at Stryker Instruments and Healthmark Industries.
Micaela Trexler, PhD
Dr. Trexler serves as a Senior Scientist for Seraph Biosciences, Inc with over eight years of laboratory research experience specializing in Raman Spectroscopy, virus identification, infectious disease diagnostics, and product development. She is primarily responsible for drafting and executing experimental designs for products on the Seraspec® platform in coordination with the company’s Engineering and Quality teams. Dr. Trexler holds a B.S. and M.Eng. in Biomedical Engineering from Boston University, and PhD in Biomedical Engineering from Wayne State University with a research focus on virus identification using Raman Spectroscopy.
Charles J. Shanley, MD
Founder & Chairman
Dr. Shanley is a co-founder and Chairman of Seraph Biosciences, Inc. He currently serves as President and Chief Executive Officer of Wayne Health and Vice Dean of Clinical Affairs at Wayne State University’s School of Medicine. Dr. Shanley also serves on the Health Care Patient Safety and Quality Study Section of the Agency for Health Care Research and Quality (AHRQ) and was appointed to the Circulatory Devices Advisory Panel at the FDA. Dr. Shanley’s research has been funded by the U.S. Army Telemedicine and Advanced Technology Research Center (TATRC); the Michigan Economic Development Corporation (MEDC) and the National Institutes of Health (NIH).
Richard Creager, PhD
Founder & Partner, NaviDx
Dr. Creager is an established executive and consultant with over 35 years of experience in the In Vitro Diagnostics (IVD) industry. He served as Senior Vice President and Chief Science Officer of Beckman Coulter, Inc., where he was responsible for the development and commercialization of novel IVD products. His roles ranged from the leading the market introduction of real-time PCR systems to overseeing the company’s strategic plan for genomics and immunoassays. Prior to joining Beckman Coulter, Dr. Creager was Vice President of Worldwide Research & Development in Sanofi Pasteur’s Diagnostics division. He is currently a co-founder and consultant at NaviDx, a firm specializing in all aspects medical diagnostic product commercialization.
Nadeem Ishaque, PhD
CIO, GE-Healthcare Imaging (Retired)
Dr. Ishaque is a seasoned executive, inventor, and scientist with over 30 years of experience in the healthcare sector. He recently retired as Chief Innovation Officer at GE Healthcare, where he spent his career as a leader in research & development, commercialization, and business strategy overseeing several product lines for the company. Dr. Ishaque has deep expertise across many technical disciplines including diagnostic imaging, molecular technologies, biomedical instrumentation, and artificial intelligence. He currently serves as a mentor and consultant to organizations requiring expertise in technology evaluation, R&D strategy, product development, commercialization, and clinical adoption.
Gary Loveman, PhD
Chairman & CEO, Well Dot, Inc.
Dr. Loveman is currently the Chairman and CEO of Well Dot, Inc. Well is an industry-leading, AI-driven health engine technology that analyzes member health triggers and promotes personalized, achievable steps toward improved health. Prior to co-founding Well, he was President of Consumer Health and Service at Aetna Inc. where he led the company’s population health, consumer engagement and clinical services areas. He also served as Chairman, CEO and President of Caesars Entertainment Corporation for seventeen years. During his tenure with the company, Dr. Loveman oversaw the expansion of Caesars into the largest and most diversified company in the gaming industry. His efforts included pioneering Caesar’s Wellness Rewards, an incentive-based health and wellness program for over 70,000 employees and their families.
Scott Merz, PhD
CEO, MC3 Cardiopulmonary
Dr. Merz is a co-founder and Chief Executive Officer of MC3 Cardiopulmonary, a company that commercializes intellectual property related to artificial heart and lung technologies. Dr. Merz has over 25 years of experience in medical device research, development, and business formation. He holds over 10 patents and has led numerous licensing deals enabling the launch of several spinout medical device companies. He is a charter member of the Extracorporeal Life Support Organization (ELSO) and long-standing leader of the cardiopulmonary community.
President, MFS & Co.
Mike Shields is a successful entrepreneur, venture capitalist, and business leader. He currently serves on the Board of Seraph Biosciences, P3 Media, and Spotted Media and actively invests in the biosciences, insurance, and media industries. He recently served as CEO of Novation Analytics, a premier provider of software and data solutions to the automotive industry. Mike was also founder and CEO of Control-Tec, a global powertrain control systems technology provider. Over the past 10 years, he served as CEO of Arrow Racing Engines, Arrow Performance Products, Power-Tec, Saleen, Cyltec, and President of Flat Rock Metal and Bar Processing. Mike is currently on the Board of the Country Club of Detroit and was Chair of the Greater Detroit Chapter and Gold Organization of the Young Presidents Organization (YPO). Prior to his business career, he was practicing attorney at Dickinson Wright and founding partner of Strobl and Manoogian. He holds his Juris Doctor from University of Notre Dame and an MBA from the University of Michigan.
Founder & COO, Medical Engineering Partners
Mr. Trexler is a co-founder of Seraph Biosciences and helps manage the day to day operations, including the strategic and operational planning activities required to help launch the company. He earned his BS degree in Chemical Engineering and an MBA with a concentration in finance. Mr. Trexler started his entrepreneurial career over twenty-five years ago by founding Technical Enviro Services, Inc. He currently serves as Chief Executive Officer of Technical Enviro Services and Chief Operating Officer of Medical Engineering Partners, LLC.
Principal & Chairman, JACK Entertainment
Matt Cullen currently serves as Principal & Chairman of JACK Entertainment LLC. JACK Entertainment is Cleveland-based gaming company which employs more than 1,400 team members and generates $400 million in annual revenues. Previously, he spent more than a decade leading gaming, real estate and other initiatives for Dan Gilbert’s Family of Companies. During that time, Matt helped lead revitalization efforts within Detroit and Cleveland totaling commitments of more than $5 billion, and served most recently as the Chief Executive Officer of Bedrock Detroit.
Founder & Chairman, Emagine Entertainment
Paul Glantz is co-founder and chairman of Michigan-based Emagine Entertainment, Inc. He has raised more than $150 million in capital to grow Emagine into a national theater chain composed of 27 world-class entertainment venues. Paul previously served as President of Proctor Financial, Inc., a leading provider of specialized insurance services to mortgage servicers nationwide. He was selected as first-ever recipient of Wayne State University’s Irvin D. Reid Honors College’s Pillar Award and also as Ernst & Young’s Entrepreneur of the Year for Michigan and Northwest Ohio.
Founder, Venshure Test Services
David Ploucha has been a leader of successful product development teams for Fortune 10, 1000, and 5000 organizations in the automotive industry for more than 25 years. He recently co-founded Venshure Test Services, an OEM supplier of vehicle testing services for EV, ICE, and advanced powertrains. Prior to his current role, David co-founded and served as President of Control-Tec, a leading global powertrain control systems technology provider until the company was acquired by Delphi Automotive, PLC.